0
Articles |

Antithrombotic Therapy in Children

Paul Monagle, MBBS; Alan D. Michelson, MD; Edward Bovill, MD; Maureen Andrew, MD, Chair
Author and Funding Information

Correspondence to: Maureen Andrew, MD, Pediatric Thrombosis and Haemostasis Program, Division of Hematology/Oncology, The Hospital for Sick Children, 555 University Ave, Toronto, Ontario, Canada; e-mail: christine.warner@sickkids.on.ca



Chest. 2001;119(1_suppl):344S-370S. doi:10.1378/chest.119.1_suppl.344S
Text Size: A A A
Published online

Extract

Antithrombotic therapy is required for the prevention and treatment of thromboembolic complications in specific pediatric patient populations. Recommendations for antithrombotic therapy in children have been loosely extrapolated from recommendations for adults because thromboembolic events in children were rare enough to hinder the testing of specific therapeutic modalities, yet were common enough to present significant management dilemmas that required therapeutic intervention.12 However, the optimal prevention and treatment of thromboembolisms (TEs) in children likely differ from those of adults because of important ontogenic features of hemostasis that affect both the pathophysiology of the thrombotic processes and the response to antithrombotic agents.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
New Antithrombotic Drugs*: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)*
PubMed Articles
Guidelines
Guideline on the assessment of bleeding risk prior to surgery or invasive procedures.
British Committee for Standards in Haematology | 4/18/2008
Antithrombotic therapy supplement.
Institute for Clinical Systems Improvement | 4/18/2008
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543